ArticleLeukemia2017

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.

C N Harrison et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.